Navigation Links
Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
Date:3/9/2009

ompany's common stock.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will satisfy Nasdaq's conditions for continued listing on The Nasdaq Capital Market, that any potential appeal or hearing for a stay of delisting from The Nasdaq Capital Market will be successful, or that the Company
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
9. FDA Struggles to Keep Pace With Requests for Generics
10. President Bush Requests Funding Cuts That Endanger Domestic Violence Victims
11. Maryland Stem Cell Commission Issues Requests for Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... HealthDay Reporter , FRIDAY, Jan. 28 (HealthDay ... a decision by a drug manufacturer to halt production ... medication,s use in lethal injections in prison executions. ... Pentothal (sodium thiopental) at its plant in Italy, but ...
... cancer surgery may help activate the body,s immune response ... lowering mood disturbance, according to a new study by ... Center. The study is published in the ... It,s the first to examine the effects pre-surgery stress ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Jan. 28 ... mantra for those who think people have become too reliant ... agree with the sentiment. They,re concerned that doctors are ... hands-on physical examination in favor of newfangled tests and scans. ...
... A team of researchers led by Vicente Gilsanz, ... Institute of Children,s Hospital Los Angeles, determined that the onset ... density, or bone strength. Length of puberty did not ... leads to osteoporosis, resulting in bones becoming increasingly brittle and ...
... Reporter , FRIDAY, Jan. 28 (HealthDay News) -- People facing ... by lack of control -- with doctors poking and prodding ... Hospice care, however, can give back some control over ... and helping both the dying person and the person,s family ...
... The Office of Naval Research,s (ONR) TechSolutions department is ... later this year new protective eyewear that will eliminate ... colored lenses to accommodate differences in light levels. ... transitional lenses commonly found at an optometrist,s office. "Transition ...
Cached Medicine News:Health News:Will Loss of Lethal Injection Drug Harm Surgical Patients? 2Health News:Will Loss of Lethal Injection Drug Harm Surgical Patients? 3Health News:Pre-surgical stress management boosts immune function, lowers mood disturbance in prostate cancer patients 2Health News:Pre-surgical stress management boosts immune function, lowers mood disturbance in prostate cancer patients 3Health News:Calls Go Out to Revive the Traditional Physical 2Health News:Calls Go Out to Revive the Traditional Physical 3Health News:Researchers discover age of onset of puberty predicts adult osteoporosis risk 2Health News:More People Choosing Hospice at Life's End 2Health News:More People Choosing Hospice at Life's End 3Health News:ONR's TechSolutions providing SEALs with new glasses that change lens color on the fly 2
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: